A Phase 2a, Randomized, Open-Label Study to Determine the Optimal Dose and Evaluate the Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS)
Latest Information Update: 28 Jan 2026
At a glance
- Drugs Progerinin (Primary) ; Lonafarnib
- Indications Progeria
- Focus Adverse reactions; Pharmacokinetics
- Sponsors PRG Science & Technology
Most Recent Events
- 23 Jan 2026 Planned End Date changed from 1 Dec 2025 to 1 Mar 2026.
- 23 Jan 2026 Planned primary completion date changed from 1 Dec 2025 to 1 Mar 2026.
- 23 Jan 2026 Status changed from recruiting to active, no longer recruiting.